Related Experiment Video
Updated: Nov 1, 2025
Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors
Published on: September 20, 2016
Only SF3B1 mutation involving K700E independently predicts overall survival in myelodysplastic syndromes
Rashmi Kanagal-Shamanna1, Guillermo Montalban-Bravo2, Koji Sasaki2
1Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Background:
SF3B1 mutations (SF3B1mut ) in myelodysplastic syndromes (MDS) frequently involve codon K700E and have a favorable prognosis. The prognostic effect of non-K700E SF3B1mut is uncertain.
Methods:
The authors analyzed the clinicopathological features and outcomes of a single-institution series of 94 treatment-naive SF3B1mut MDS patients (18%) and 415 treatment-naive SF3B1wt MDS patients and explored the differences between K700E and non-K700E SF3B1mut MDS.
Results:
Fifty-five patients (59%) carried K700E. Recurrent non-K700E mutations (39 [41%]) included R625, H662, and K666. Compared with SF3B1mut K700E patients, non-K700E patients had a lower median absolute neutrophil count (1.8 vs 2.4; P = .005) and were frequently "high" according to the Revised International Prognostic Scoring System (19% vs 4%; P = .031). Non-K700E MDS was associated frequently with RUNX1 (26% vs 7%; P = .012) and exclusively with BCOR, IDH2, and SRSF2 mutations. A splicing analysis showed the differential distribution of alternatively spliced events and gene expression profiles between K700 and non-K700E MDS patients. The majority (at least 80%) of SF3B1mut K700E, SF3B1mut non-K700E, and SF3B1wt patients were treated with hypomethylating agents. Over a median follow-up of 16 months, SF3B1mut had superior overall survival (OS) in comparison with SF3B1wt in all MDS patients (not reached vs 25.2 months; P = .0003), in patients with low-grade MDS, and in patients with myelodysplastic syndromes with ring sideroblasts (MDS-RS). Compared with SF3B1wt , SF3B1mut K700E had superior outcomes in all MDS (median OS, 25 months vs not reached; P = .0001), in low-grade MDS (median OS, 41.3 months vs not reached; P = .0015), and in MDS-RS (median OS, 22.3 months vs not reached; P = .0001), but no significant difference was seen between non-K700E and SF3B1wt MDS. By multivariable analysis, the absence of SF3B1mut K700E mutations was independently associated with the prognosis.
Conclusions:
This study highlights the importance of the SF3B1 mutation subtype in MDS risk assessment.
Lay Summary:
Myelodysplastic syndromes (MDS) with SF3B1 mutations are regarded as having a favorable prognosis by both the World Health Organization and the International Working Group for the Prognosis of Myelodysplastic Syndromes. However, this article shows that only MDS patients with SF3B1 K700E mutations have a favorable prognosis (and not MDS patients with SF3B1 mutations involving other codons). This has important implications for refining future MDS subclassification and risk assessment criteria.
Insights
SF3B1 K700E mutations in myelodysplastic syndromes (MDS) indicate a favorable prognosis, unlike other SF3B1 mutations. This finding is crucial for refining MDS risk assessment and subclassification.
Area of Science:
- Hematology
- Oncology
- Molecular Biology
Background:
- SF3B1 mutations are common in myelodysplastic syndromes (MDS) and typically associated with a favorable prognosis.
- The prognostic impact of SF3B1 mutations not involving codon K700E remains unclear.
Purpose of the Study:
- To investigate the clinical and prognostic differences between K700E and non-K700E SF3B1 mutations in treatment-naive MDS patients.
- To explore the impact of SF3B1 mutation subtypes on overall survival and associated genetic mutations.
Main Methods:
- Analysis of clinicopathological features and outcomes in 94 SF3B1-mutated and 415 SF3B1-wildtype MDS patients.
- Comparison of outcomes between SF3B1 K700E, non-K700E mutated, and SF3B1 wildtype MDS.
- Splicing analysis and gene expression profiling to understand molecular differences.
Main Results:
- SF3B1 K700E mutations confer a favorable prognosis, similar to SF3B1 wildtype in some analyses.
- Non-K700E SF3B1 mutations were associated with lower neutrophil counts, higher risk scores, and distinct co-mutations (RUNX1, BCOR, IDH2, SRSF2).
- SF3B1 mutations, particularly K700E, were linked to superior overall survival compared to SF3B1 wildtype MDS.
Conclusions:
- SF3B1 mutation subtype is critical for accurate MDS risk stratification.
- Only SF3B1 K700E mutations are associated with a favorable prognosis in MDS.
- Findings necessitate refinement of MDS classification and risk assessment criteria.
